AOD-9604 Research: What the Studies Show
AOD-9604 is one of the few research peptides with a large, properly controlled human dataset — and the honest summary is that the fat-loss effect seen in rodents did not carry over. Here is each study, including the trial that ended its development.
Mechanism of action
AOD-9604 is a synthetic analogue of the C-terminal 177-191 fragment of human growth hormone. It isolates the region associated with fat metabolism while leaving out the parts of the hormone that drive systemic growth signalling.
The mechanism established in rodents runs through the β3-adrenergic receptor: the peptide upregulates repressed β3-AR RNA in obese adipose tissue and increases lipolytic activity. In β3-AR knock-out mice the fat-loss effect disappears entirely.
Because it does not act on the growth-hormone receptor in the usual way, it does not raise serum IGF-1 or disturb glucose handling — the property that made it attractive, and the one that held up in humans even when efficacy did not.
The studies
The cards below are ordered by how much weight the evidence carries. The largest and most rigorous human trial is first, because it is the one that determined the compound's fate.
Pivotal human efficacy
24-week phase IIb randomised, double-blind, placebo-controlled obesity trial
Whether oral AOD-9604 produces clinically meaningful weight loss against placebo at scale.
Randomised, double-blind, placebo-controlled · 536 obese subjects · 24 weeks · oral AOD-9604 alongside a formal diet and exercise programme
- 536
- Subjects
- Not met
- Primary endpoint
- Terminated Feb 2007
- Programme outcome
- The treatment failed to achieve statistically significant weight loss over placebo at both primary and secondary endpoints.
- Metabolic Pharmaceuticals ended the anti-obesity development programme in February 2007 because the observed weight loss was too small to justify commercial production.
- This is the single most important study on the compound, and it is a negative result — any claim of human fat-loss efficacy has to answer to it.
Human safety & tolerability
Safety and tolerability meta-analysis across six controlled human trials
Pooling the full human safety record for AOD-9604 across every controlled trial run.
Meta-analysis of six randomised, double-blind, placebo-controlled trials · 893 healthy, overweight and obese adults · IGF-1, glucose tolerance, insulin sensitivity and immunogenicity endpoints
- 893
- Subjects pooled
- No increase
- Serum IGF-1
- Unchanged
- Glucose tolerance
- None elicited
- Anti-AOD9604 antibodies
- The safety profile was indistinguishable from placebo across nearly 900 subjects — an unusually strong dataset for a peptide in this space.
- Unlike intact human growth hormone, chronic oral dosing did not raise IGF-1, cause insulin resistance or worsen oral glucose tolerance.
- Efficacy for weight loss was absent or inconsistent throughout. The compound is well characterised as safe, not as effective.
Earlier human efficacy signal
12-week multi-centre dose-ranging phase II trial
Dose-ranging assessment of oral AOD-9604 in severely obese patients.
Multi-centre, dose-ranging · 300 obese patients (BMI ≥ 35 kg/m²) · 12 weeks · oral daily doses from 1 mg to 10 mg
- 2.6-2.8 kg
- 1 mg/day weight loss
- 0.8 kg
- Placebo weight loss
- Absent — higher doses did worse
- Dose response
- This is the trial that generated the early optimism, and the numbers people still quote today come from here.
- The lack of a dose-dependent effect was a warning sign: 10 mg/day produced less weight loss than 1 mg/day, which is not how a real pharmacological effect usually behaves.
- The signal did not repeat in the larger, longer 536-subject phase IIb trial three years later.
Pre-clinical mechanism
Chronic hGH 177-191 dosing in obese Zucker rats and β3-AR knock-out mice
Establishing whether the isolated fragment burns fat, and through which receptor pathway.
Endocrinology · obese Zucker rats and β3-adrenergic receptor knock-out mice · oral 500 μg/kg daily for 19 days · body weight gain, adipose lipolysis and β3-AR RNA endpoints
- Reduced >50%
- Body weight gain
- Significantly increased
- Adipose lipolysis
- No fat loss
- β3-AR knock-out mice
- The strongest efficacy data on the compound, and it is entirely rodent — over 50% reduction in body weight gain in obese animals.
- It restored repressed β3-adrenergic receptor RNA in obese fat cells to lean-control levels, which explains the lipolytic effect.
- The knock-out arm is the elegant part: with the β3 receptor removed the effect vanished, proving the mechanism depends on that specific pathway.
Storage & handling
AOD-9604 is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake.
Store reconstituted solution at 2-8 °C and use within the stability window set by your lab's standard operating procedures.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.